DCF — BAYLOR S&W MEDICAL CENTER - IRVING
Enterprise Value: $-483.9M
🛡️ Public data only — no PHI permitted on this instance.
← DashboardPRFProfileMEMIC MemoBRGBridgeCIComp IntelSCNScenariosAIMLDCFDCFLBOLBOFIN3-StmtMKTMarketDENDenialRETReturnsLVRLeversWFLWaterfallPLYPlaybookTRDTrendsPREDPredictedMEM2Memo
$-483.9M
Enterprise Value
$-151.4M
PV of Cash Flows
$-332.5M
PV of Terminal Value
$-535.5M
Terminal Value
10.0%
WACC
2.5%
Terminal Growth
Cash Flow Projections
PROJ| Year | Revenue | EBITDA | Margin | FCF | PV(FCF) |
|---|---|---|---|---|---|
| Year 1 | $252.0M | $-31.1M | -12.0% | $-41.7M | $-37.9M |
| Year 2 | $259.6M | $-29.4M | -11.0% | $-40.4M | $-33.4M |
| Year 3 | $267.4M | $-27.6M | -10.0% | $-38.9M | $-29.3M |
| Year 4 | $275.4M | $-27.1M | -10.0% | $-38.7M | $-26.5M |
| Year 5 | $283.6M | $-27.2M | -10.0% | $-39.2M | $-24.3M |
Interpretation
INTAt a WACC of 10.0% and terminal growth of 2.5%, enterprise value is $-483.9M. Terminal value accounts for 0% of total EV — consider sensitivity to terminal assumptions.
Next steps: Check the LBO model to see equity returns at this entry price, or the EBITDA bridge to model value creation levers.
Assumptions
ASSMrevenue base$244.7M
revenue growth rates[0.03, 0.03, 0.03, 0.03, 0.03]
ebitda margin base-0.1283098099258781
ebitda margin improvement bps[50, 100, 100, 50, 25]
capex pct revenue0.04
nwc pct revenue0.08
tax rate0.25
projection years5